Literature DB >> 16858271

Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis.

Atul Humar1.   

Abstract

A series of substudies of a large international cytomegalovirus (CMV) prophylaxis trial investigated the incidence and clinical relevance of reactivation of human herpesviruses 6, 7, and 8, varicella zoster virus, Epstein-Barr virus, polyomavirus, and adenovirus, and the effect of CMV prophylaxis on clinical and subclinical non-CMV viral infections, in adult solid organ transplant (SOT) patients. Results of the substudy analyses showed that viremia caused by a number of viruses is surprisingly common posttransplantation; most of these infections likely represent reactivation of endogenous latent virus. In addition, although infection or active viral replication was common in this cohort of SOT patients, symptomatic disease due to these viruses was uncommon and the clinical sequelae of viremia were unclear or not apparent. CMV prophylaxis may have modified the natural history of some of these non-CMV viral infections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16858271     DOI: 10.1097/01.tp.0000230432.39447.8b

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  18 in total

Review 1.  Viral infections in lung transplant recipients.

Authors:  Pali Dedhiya Shah; John F McDyer
Journal:  Semin Respir Crit Care Med       Date:  2010-03-30       Impact factor: 3.119

2.  Treating HSV and CMV reactivations in critically ill patients who are not immunocompromised: pro.

Authors:  Jean-Marie Forel; Ignacio Martin-Loeches; Charles-Edouard Luyt
Journal:  Intensive Care Med       Date:  2014-11-01       Impact factor: 17.440

Review 3.  Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway.

Authors:  Thomas J Gardner; Domenico Tortorella
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-15       Impact factor: 11.056

4.  Adenovirus disease in six small bowel, kidney and heart transplant recipients; pathology and clinical outcome.

Authors:  Vikas Mehta; Pauline C Chou; Maria M Picken
Journal:  Virchows Arch       Date:  2015-09-16       Impact factor: 4.064

5.  Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients.

Authors:  Diana F Florescu; Steven A Pergam; Michael N Neely; Fang Qiu; Christine Johnston; SingSing Way; Jane Sande; Deborah A Lewinsohn; Judith A Guzman-Cottrill; Michael L Graham; Genovefa Papanicolaou; Joanne Kurtzberg; Joseph Rigdon; Wendy Painter; Herve Mommeja-Marin; Randall Lanier; Maggie Anderson; Charles van der Horst
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-29       Impact factor: 5.742

6.  Transient detection of E1-containing adenovirus in saliva after the delivery of a first-generation adenoviral vector to human parotid gland.

Authors:  Changyu Zheng; Nikolay P Nikolov; Ilias Alevizos; Ana P Cotrim; Shuying Liu; Linda McCullagh; John A Chiorini; Gabor G Illei; Bruce J Baum
Journal:  J Gene Med       Date:  2010-01       Impact factor: 4.565

7.  Trichodysplasia of immunosuppression treated with oral valganciclovir.

Authors:  Aton M Holzer; Lauren C Hughey
Journal:  J Am Acad Dermatol       Date:  2009-01       Impact factor: 11.527

8.  Varicella zoster virus (VZV) in solid organ transplant recipients.

Authors:  S A Pergam; A P Limaye
Journal:  Am J Transplant       Date:  2009-12       Impact factor: 8.086

9.  Varicella zoster virus in solid organ transplantation.

Authors:  S A Pergam; A P Limaye
Journal:  Am J Transplant       Date:  2013-03       Impact factor: 8.086

10.  Immune Monitoring of Infectious Complications in Transplant Patients: an Important Step towards Improved Clinical Management.

Authors:  Rajiv Khanna
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.